Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

clofazimine

  • <em>In Vitro</em> Susceptibility of <span class="named-content genus-species" id="named-content-1">Nocardia farcinica</span> to the Antimycobacterial Drug Clofazimine
    Letter to the Editor
    In Vitro Susceptibility of Nocardia farcinica to the Antimycobacterial Drug Clofazimine
    Ka Lip Chew, Sophie Octavia, Siang Fei Yeoh, Jeanette W. P. Teo
  • Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of <em>Mycobacterium avium</em> Infection
    Experimental Therapeutics
    Synergistic Activity of Clofazimine and Clarithromycin in an Aerosol Mouse Model of Mycobacterium avium Infection

    Infections with nontuberculous mycobacteria (NTM) have a poor prognosis in patients with underlying respiratory diseases. Clofazimine (CFZ) showed both experimental and clinical promising results against clinically relevant NTM. However, there are no data on CFZ in combination with the current recommended treatment; therefore, we aimed to study its in vivo activity in an aerosol mouse model of...

    Jean-Philippe Lanoix, Cédric Joseph, François Peltier, Sandrine Castelain, Claire Andréjak
  • Assessment of Clofazimine and TB47 Combination Activity against <span class="named-content genus-species" id="named-content-1">Mycobacterium abscessus</span> Using a Bioluminescent Approach
    Experimental Therapeutics
    Assessment of Clofazimine and TB47 Combination Activity against Mycobacterium abscessus Using a Bioluminescent Approach

    Mycobacterium abscessus is intrinsically resistant to most antimicrobial agents. The emerging infections caused by M. abscessus and the lack of effective treatment call for rapid attention. Here, we intended to construct a selectable marker-free autoluminescent...

    Yang Liu, Yaoju Tan, M. Mahmudul Islam, Yuanyuan Cao, Xiaoyun Lu, Sheng Zeng, H. M. Adnan Hameed, Peipei Zhou, Xingshan Cai, Shuai Wang, Julius N. Mugweru, Guoliang Zhang, Huancai Yin, Jianxiong Liu, Eric Nuermberger, Tianyu Zhang
  • Free
    Successful Systemic and Topical Treatment of <span class="named-content genus-species" id="named-content-1">Mycobacterium abscessus</span> Otomastoiditis
    Editor's Pick Challenging Clinical Case in Antimicrobial Resistance
    Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis

    Mycobacterium abscessus is an extensively drug-resistant opportunistic pathogen that can cause chronic otomastoiditis. There are no evidence-based treatment regimens for this severe infection. We treated four children with M. abscessus otomastoiditis with a structured regimen of topical imipenem and...

    Floor van Wijk, Jérôme Waterval, Koen van Aerde, Stefanie S. V. Henriet, F. J. Anton Meijer, Lennaert C. Borra, Rob E. Aarnoutse, Jakko van Ingen
  • The TetR Family Transcription Factor MAB_2299c Regulates the Expression of Two Distinct MmpS-MmpL Efflux Pumps Involved in Cross-Resistance to Clofazimine and Bedaquiline in <span class="named-content genus-species" id="named-content-1">Mycobacterium abscessus</span>
    Mechanisms of Resistance
    The TetR Family Transcription Factor MAB_2299c Regulates the Expression of Two Distinct MmpS-MmpL Efflux Pumps Involved in Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus

    Mycobacterium abscessus is a human pathogen responsible for severe respiratory infections, particularly in patients with underlying lung disorders. Notorious for being highly resistant to most antimicrobials, new therapeutic approaches are needed to successfully treat M. abscessus-infected patients...

    Ana Victoria Gutiérrez, Matthias Richard, Françoise Roquet-Banères, Albertus Viljoen, Laurent Kremer
  • Open Access
    Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan
    Mechanisms of Resistance
    Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan

    We report on the first six cases of acquired resistance to bedaquiline in Pakistan. Seventy sequential isolates from 30 drug-resistant-tuberculosis patients on bedaquiline-containing regimens were retrospectively tested for bedaquiline resistance by MIC testing and by the detection of mutations in relevant genes. We documented cases failing therapy that developed specific mutations in Rv0678 and had increased MICs associated...

    Arash Ghodousi, Alamdar Hussain Rizvi, Aurangzaib Quadir Baloch, Abdul Ghafoor, Faisal Masood Khanzada, Mehmood Qadir, Emanuele Borroni, Alberto Trovato, Sabira Tahseen, Daniela Maria Cirillo
  • Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting <span class="named-content genus-species" id="named-content-1">Mycobacterium ulcerans</span> Gene Decay
    Experimental Therapeutics
    Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay

    Buruli ulcer is treatable with antibiotics. An 8-week course of rifampin (RIF) and either streptomycin (STR) or clarithromycin (CLR) cures over 90% of patients.

    Paul J. Converse, Deepak V. Almeida, Sandeep Tyagi, Jian Xu, Eric L. Nuermberger
  • Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis
    Experimental Therapeutics
    Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis

    Clofazimine and high-dose rifapentine have each separately been associated with treatment-shortening activity when incorporated into tuberculosis (TB) treatment regimens. We hypothesized that both modifications, i.e., the addition of clofazimine and the replacement of rifampin with high-dose rifapentine, in the first-line regimen for drug-susceptible TB would significantly shorten the duration of treatment necessary for cure.

    ...
    Vikram Saini, Nicole C. Ammerman, Yong Seok Chang, Rokeya Tasneen, Richard E. Chaisson, Sanjay Jain, Eric Nuermberger, Jacques H. Grosset
  • <em>In Vitro</em> and <em>In Vivo</em> Activities of the Riminophenazine TBI-166 against <em>Mycobacterium tuberculosis</em>
    Experimental Therapeutics
    In Vitro and In Vivo Activities of the Riminophenazine TBI-166 against Mycobacterium tuberculosis

    The riminophenazine agent clofazimine (CFZ) is repurposed as an important component of the new short-course multidrug-resistant tuberculosis regimen and significantly shortens first-line regimen for drug-susceptible tuberculosis in mice. However, CFZ use is hampered by its unwelcome skin discoloration in patients.

    Jian Xu, Bin Wang, Lei Fu, Hui Zhu, Shaochen Guo, Haihong Huang, Dali Yin, Ye Zhang, Yu Lu
  • Clofazimine Exposure <em>In Vitro</em> Selects Efflux Pump Mutants and Bedaquiline Resistance
    Mechanisms of Resistance
    Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance

    Six in vitro clofazimine-resistant spontaneous mutants obtained from a wild-type or pyrazinamide-resistant ATCC reference strain were selected to evaluate bedaquiline cross-resistance. The reverse was conducted for bedaquiline mutants.

    Nabila Ismail, Remco P. H. Peters, Nazir A. Ismail, Shaheed V. Omar

Pages

  • Next
  • 1
  • 2
  • 3
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596